美国食品药品监督管理局（FDA）已正式认可Rexlemestrocel-L在缓解疼痛强度方面表现出显著优势。最新数据显示，该疗法在12个月内持续减轻背痛的效果，进一步验证了其临床有效性。这一进展为MESOBLAST LTD旗下产品的应用前景提供了有力支撑。
美国食品药品监督管理局（FDA）已正式认可Rexlemestrocel-L在缓解疼痛强度方面表现出显著优势。最新数据显示，该疗法在12个月内持续减轻背痛的效果，进一步验证了其临床有效性。这一进展为MESOBLAST LTD旗下产品的应用前景提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.